The requirement to prove the value of new healthcare interventions to stakeholders beyond those with clinical responsibilities exists in most countries across the globe. We recognise that success in global market access requires a thorough understanding of the changing market landscape and the payer environment. Specific, robust evidence highlighting clinical benefit and economic value of a treatment is required to convince payers to invest in new healthcare interventions. This requirement for definition of value extends beyond drugs to include medical devices, diagnostics, and medical nutrition.
We understand that the experience and resources required to prepare for successful global market access varies across pharmaceutical organisations. We apply insight from over twenty years’ experience in Health Technology Assessment (HTA) and value proposition development to our strategic consulting and roadmap services. Our comprehensive expertise enables us to support global market access teams with strategic consulting, value proposition development, innovative roadmap strategies, and tactical support with market access initiatives such as global HTA.
Our global market access products and services support pharmaceutical, biotech, and medical device companies with: